PARP1 inhibitor

DRUG CLASS:

PARP1 inhibitor

News alerts, weekly reports and conference planners

Related drugs:

BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	abiraterone/niraparib Sensitive: A1 - Approval abiraterone / niraparib Sensitive : A1	abiraterone/niraparib Sensitive: A1 - Approval abiraterone / niraparib Sensitive : A1
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	abiraterone/niraparib Sensitive: A1 - Approval abiraterone / niraparib Sensitive : A1	abiraterone/niraparib Sensitive: A1 - Approval abiraterone / niraparib Sensitive : A1
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	JPI-547 Sensitive: C2 – Inclusion Criteria JPI-547 Sensitive : C2	JPI-547 Sensitive: C2 – Inclusion Criteria JPI-547 Sensitive : C2
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3
BRCA1 mutation	Peritoneal Cancer	BRCA1 mutation	Peritoneal Cancer	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3
BRCA2 mutation	Peritoneal Cancer	BRCA2 mutation	Peritoneal Cancer	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3
BRCA2 mutation	Fallopian Tube Cancer	BRCA2 mutation	Fallopian Tube Cancer	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3
BRCA1 mutation	Fallopian Tube Cancer	BRCA1 mutation	Fallopian Tube Cancer	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3
BRCA2 mutation	Pancreatic Cancer	BRCA2 mutation	Pancreatic Cancer	BSI 201 Sensitive: C4 – Case Studies BSI 201 Sensitive : C4	BSI 201 Sensitive: C4 – Case Studies BSI 201 Sensitive : C4
BRCA2 mutation	Non Small Cell Lung Cancer	BRCA2 mutation	Non Small Cell Lung Cancer	JPI-547 Sensitive: C4 – Case Studies JPI-547 Sensitive : C4	JPI-547 Sensitive: C4 – Case Studies JPI-547 Sensitive : C4
ATM mutation	Breast Cancer	ATM mutation	Breast Cancer	JPI-547 Sensitive: C4 – Case Studies JPI-547 Sensitive : C4	JPI-547 Sensitive: C4 – Case Studies JPI-547 Sensitive : C4
BRCA2 mutation	Breast Cancer	BRCA2 mutation	Breast Cancer	JPI-547 Sensitive: C4 – Case Studies JPI-547 Sensitive : C4	JPI-547 Sensitive: C4 – Case Studies JPI-547 Sensitive : C4
BRCA1 mutation	Breast Cancer	BRCA1 mutation	Breast Cancer	JPI-547 Sensitive: C4 – Case Studies JPI-547 Sensitive : C4	JPI-547 Sensitive: C4 – Case Studies JPI-547 Sensitive : C4
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	AZD5305 Sensitive: D – Preclinical AZD5305 Sensitive : D	AZD5305 Sensitive: D – Preclinical AZD5305 Sensitive : D
BRCA2 mutation	Breast Cancer	BRCA2 mutation	Breast Cancer	TQB3823 Sensitive: D – Preclinical TQB3823 Sensitive : D	TQB3823 Sensitive: D – Preclinical TQB3823 Sensitive : D
BRCA1 mutation	Breast Cancer	BRCA1 mutation	Breast Cancer	TQB3823 Sensitive: D – Preclinical TQB3823 Sensitive : D	TQB3823 Sensitive: D – Preclinical TQB3823 Sensitive : D
HRD	HER2 Positive Breast Cancer	HRD	HER2 Positive Breast Cancer	fam-trastuzumab deruxtecan-nxki + AZD5305 Sensitive: D – Preclinical fam-trastuzumab deruxtecan-nxki + AZD5305 Sensitive : D	fam-trastuzumab deruxtecan-nxki + AZD5305 Sensitive: D – Preclinical fam-trastuzumab deruxtecan-nxki + AZD5305 Sensitive : D
PARP1 underexpression	Soft Tissue Sarcoma	PARP1 underexpression	Soft Tissue Sarcoma	ATR inhibitor + PARP1 inhibitor Sensitive: D – Preclinical ATR inhibitor + PARP1 inhibitor Sensitive : D	ATR inhibitor + PARP1 inhibitor Sensitive: D – Preclinical ATR inhibitor + PARP1 inhibitor Sensitive : D
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	OX425 Sensitive: D – Preclinical OX425 Sensitive : D	OX425 Sensitive: D – Preclinical OX425 Sensitive : D
BRCA1 mutation	Breast Cancer	BRCA1 mutation	Breast Cancer	olaparib + OX425 Sensitive: D – Preclinical olaparib + OX425 Sensitive : D	olaparib + OX425 Sensitive: D – Preclinical olaparib + OX425 Sensitive : D
HRD	Colorectal Adenocarcinoma	HRD	Colorectal Adenocarcinoma	AZD5305 Sensitive: D – Preclinical AZD5305 Sensitive : D	AZD5305 Sensitive: D – Preclinical AZD5305 Sensitive : D
HRD	Breast Cancer	HRD	Breast Cancer	AZD5305 Sensitive: D – Preclinical AZD5305 Sensitive : D	AZD5305 Sensitive: D – Preclinical AZD5305 Sensitive : D
HRD	Pancreatic Ductal Adenocarcinoma	HRD	Pancreatic Ductal Adenocarcinoma	JPI-547 Sensitive: D – Preclinical JPI-547 Sensitive : D	JPI-547 Sensitive: D – Preclinical JPI-547 Sensitive : D
RNF43 mutation	Pancreatic Ductal Adenocarcinoma	RNF43 mutation	Pancreatic Ductal Adenocarcinoma	JPI-547 Sensitive: D – Preclinical JPI-547 Sensitive : D	JPI-547 Sensitive: D – Preclinical JPI-547 Sensitive : D
HRD	Solid Tumor	HRD	Solid Tumor	OX425 Sensitive: D – Preclinical OX425 Sensitive : D	OX425 Sensitive: D – Preclinical OX425 Sensitive : D
VTCN1 underexpression	Solid Tumor	VTCN1 underexpression	Solid Tumor	AZD5305 + AZD8205 Sensitive: D – Preclinical AZD5305 + AZD8205 Sensitive : D	AZD5305 + AZD8205 Sensitive: D – Preclinical AZD5305 + AZD8205 Sensitive : D

PARP1 inhibitor

PARP1 inhibitor

Associations(27)

Associations
(27)